Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 488

1.

Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

Kauff ND, Barakat RR.

J Clin Oncol. 2007 Jul 10;25(20):2921-7. Review.

PMID:
17617523
2.

Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.

Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ.

Am J Surg Pathol. 2009 Aug;33(8):1125-36. doi: 10.1097/PAS.0b013e31819e986a.

PMID:
19440148
3.

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K.

N Engl J Med. 2002 May 23;346(21):1609-15.

4.
5.

Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.

Rabban JT, Crawford B, Chen LM, Powell CB, Zaloudek CJ.

Am J Surg Pathol. 2009 Jan;33(1):111-9. doi: 10.1097/PAS.0b013e31817d74a7.

PMID:
18830124
6.

Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.

Gabriel CA, Tigges-Cardwell J, Stopfer J, Erlichman J, Nathanson K, Domchek SM.

Fam Cancer. 2009;8(1):23-8. doi: 10.1007/s10689-008-9208-6.

PMID:
18758995
7.

Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.

Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ.

Am J Surg Pathol. 2009 Dec;33(12):1878-85. doi: 10.1097/PAS.0b013e3181bc6059.

PMID:
19898224
8.

Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.

Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM.

Am J Obstet Gynecol. 2006 Jun;194(6):1702-9.

PMID:
16731090
9.

Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.

Giannini G, Capalbo C, Ristori E, Ricevuto E, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A.

Breast Cancer Res Treat. 2006 Nov;100(1):83-91.

PMID:
16847550
10.

Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.

Meyer P, Voigtlaender T, Bartram CR, Klaes R.

Hum Mutat. 2003 Sep;22(3):259.

PMID:
12938098
11.

Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.

Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J.

J Clin Oncol. 2005 Jan 1;23(1):127-32.

PMID:
15625367
12.

Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families.

Kang HC, Kim IJ, Park JH, Kwon HJ, Won YJ, Heo SC, Lee SY, Kim KH, Shin Y, Noh DY, Yang DH, Choe KJ, Lee BH, King SB, Park JG.

Hum Mutat. 2002 Sep;20(3):235.

PMID:
12204006
13.

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR.

J Clin Oncol. 2008 Mar 10;26(8):1331-7. doi: 10.1200/JCO.2007.13.9626.

14.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

15.

A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.

Michelsen TM, Dørum A, Dahl AA.

Gynecol Oncol. 2009 Apr;113(1):128-33. doi: 10.1016/j.ygyno.2008.12.024. Review.

PMID:
19178933
16.

BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.

Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somasundaram K.

J Biosci. 2009 Sep;34(3):415-22.

17.

Management updates for women with a BRCA1 or BRCA2 mutation.

Nusbaum R, Isaacs C.

Mol Diagn Ther. 2007;11(3):133-44. Review.

PMID:
17570734
18.

Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis.

Escobar PF, Starks DC, Fader AN, Barber M, Rojas-Espalliat L.

Gynecol Oncol. 2010 Oct;119(1):43-7. doi: 10.1016/j.ygyno.2010.05.026.

PMID:
20579712
19.

Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations.

Olopade OI, Artioli G.

Breast J. 2004 Jan-Feb;10 Suppl 1:S5-9. Review.

PMID:
14984481
20.

Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.

Finch A, Metcalfe K, Lui J, Springate C, Demsky R, Armel S, Rosen B, Murphy J, Elit L, Sun P, Narod S.

Clin Genet. 2009 Mar;75(3):220-4.

PMID:
19263514
Items per page

Supplemental Content

Support Center